The possibility that GRM1/mGluR1 may be uniquely qualified to serve as a viable target for melanoma therapies was assessed in vitro and in vivo with riluzole (Rilutek®), an FDA-approved treatment for Amyotrophic Lateral Sclerosis (ALS) [66,67]. Here, GRM1 is linked to amyotrophic lateral sclerosis.